Drug Profile
Iralukast
Alternative Names: CGP 45715A; Iralukast sodiumLatest Information Update: 08 Nov 1999
Price :
$50
*
At a glance
- Originator Novartis
- Class Antiallergics; Antiasthmatics; Benzopyrans
- Mechanism of Action Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 08 Nov 1999 No-Development-Reported for Asthma in Switzerland (Inhalation)
- 08 Nov 1999 No-Development-Reported for Asthma in Switzerland (IV-injection)
- 08 Nov 1999 No-Development-Reported for Asthma in USA (Unknown route)